Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 2:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 811 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Antiretroviral Therapy Clear all
Withdrawn Phase 2 Interventional

PRO 140 for Human Immunodeficiency Virus

NCT02438345
View directory record Official record
Conditions
HIV
Interventions
PRO 140
Biological
Lead sponsor
Drexel University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Phildadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 29, 2026, 2:09 AM EDT
Completed No phase listed Observational

Long-term Effects of Highly Active Anti-Retroviral Therapy on HIV-Infected Children

NCT00260806
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
2 Years to 18 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
8
States / cities
Miami, Florida • Chicago, Illinois • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Sep 29, 2026, 2:09 AM EDT
Completed Phase 1 Interventional

Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART

NCT05144386
View directory record Official record
Conditions
HIV-1-infection
Interventions
EBT-101
Biological
Lead sponsor
Excision BioTherapeutics
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
San Francisco, California • St Louis, Missouri • Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 1, 2024 · Synced Sep 29, 2026, 2:09 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS

NCT06252402
View directory record Official record
Conditions
HIV-1
Interventions
CMV/HIV-CAR T Cells
Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Duarte, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 29, 2026, 2:09 AM EDT
Completed Phase 2 Interventional Results available

Early ART to Limit Infection and Establishment of Reservoir

NCT02859558
View directory record Official record
Conditions
HIV-1 Infection
Interventions
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • San Diego, California • Torrance, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Sep 29, 2026, 2:09 AM EDT
Completed Phase 3 Interventional Results available

Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults

NCT00118898
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir/Lamivudine, Atazanavir, Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate, Ritonavir, Abacavir/Lamivudine placebo, Emtricitabine/Tenofovir disoproxil fumarate placebo
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
16 Years and older
Enrollment
1,864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
51
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 29, 2026, 2:09 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea

NCT04192487
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, Healthy Volunteers, HIV/AIDS, HIV Diarrhea, Human Immunodeficiency Virus
Interventions
Crofelemer delayed-release tablets 125mg
Drug
Lead sponsor
Napo Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
3
States / cities
Tustin, California • Stratford, Connecticut • Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Sep 29, 2026, 2:09 AM EDT
Active, not recruiting Not applicable Interventional

Intervention to Improve HIV Care Retention by Addressing Stigma Stigmatized Environments

NCT05110963
View directory record Official record
Conditions
HIV I Infection
Interventions
Uniform Standard of Care Counseling, Behavioral Self-Regulation Skills Counseling, Behavioral Self-Regulation Skills Counseling + Stigma Management
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years and older
Enrollment
3,771 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Storrs, Connecticut • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Sep 29, 2026, 2:09 AM EDT
Terminated Phase 4 Interventional

Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIV

NCT04249037
View directory record Official record
Conditions
HIV/AIDS
Interventions
bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF), Standard initiation of antiretroviral therapy (ART)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
15 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Aurora, Colorado • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Sep 29, 2026, 2:09 AM EDT
Approved For Marketing No phase listed Expanded access

TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.

NCT00245739
View directory record Official record
Conditions
HIV Infections
Interventions
TMC-114
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
202
States / cities
Anniston, Alabama • Birmingham, Alabama • Mesa, Arizona + 199 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Sep 29, 2026, 2:09 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects

NCT00098748
View directory record Official record
Conditions
HIV Infections
Interventions
Optimized Background Therapy (OBT), maraviroc (UK-427,857)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
16 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2010 · Synced Sep 29, 2026, 2:09 AM EDT
Completed Phase 3 Interventional Results available

TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.

NCT00540449
View directory record Official record
Conditions
HIV Infections, HIV-1, Human Immunodeficiency Virus Type 1
Interventions
TMC278, Efavirenz
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years to 99 Years
Enrollment
694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Sep 29, 2026, 2:09 AM EDT
Completed Phase 4 Interventional

QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection

NCT00232908
View directory record Official record
Conditions
HIV Infections
Interventions
ARV regimen, enfuvirtide [Fuzeon]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
103
States / cities
Phoenix, Arizona • Bakersfield, California • Berkeley, California + 78 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 29, 2026, 2:09 AM EDT
Completed Not applicable Interventional

Medications for Chronic HIV: Education and Collaboration

NCT01038076
View directory record Official record
Conditions
HIV Infections, Acquired Immunodeficiency Syndrome, Medication Adherence
Interventions
MedCHEC Tablet Computer & Adherence Care
Behavioral
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Sep 29, 2026, 2:09 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Use of Memantine In Combination With Anti-HIV Drugs to Treat AIDS Dementia Complex (ADC)

NCT00000867
View directory record Official record
Conditions
AIDS Dementia Complex, HIV Infections
Interventions
Memantine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2013 · Synced Sep 29, 2026, 2:09 AM EDT
Completed Phase 4 Interventional

Intermittent Versus Continuous Medication in the Treatment of HIV

NCT00001967
View directory record Official record
Conditions
HIV Infection
Interventions
HAART
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 29, 2026, 2:09 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Doravirine and Weight Gain in Antiretroviral Naive

NCT05457530
View directory record Official record
Conditions
Body Weight Changes, Human Immunodeficiency Virus, ART, Obesity, Minority Health, BMD, Metabolic Syndrome, Fasting
Interventions
DOR/3TC/TDF, DOR + FTC/TAF, BIC/FTC/TAF
Drug · Combination Product
Lead sponsor
Prism Health North Texas
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Sep 29, 2026, 2:09 AM EDT
Completed Phase 1 Interventional

HIV Vaccine Designed for HIV Infected Adults Taking Anti-HIV Drugs

NCT00056758
View directory record Official record
Conditions
HIV Infections
Interventions
Autologous Dendritic Cell HIV Vaccination
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 26, 2007 · Synced Sep 29, 2026, 2:09 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

NCT00799864
View directory record Official record
Conditions
HIV-1
Interventions
Rilpivirine, Zidovudine, Abacavir, Tenofovir disoproxil fumarate, Lamivudine, Emtricitabine
Drug
Lead sponsor
Janssen Sciences Ireland UC
Industry
Eligibility
6 Years to 17 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
2
States / cities
Syracuse, New York • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Sep 29, 2026, 2:09 AM EDT
Completed Phase 3 Interventional

A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects.

NCT00002199
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine/Zidovudine, Abacavir sulfate
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
16 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 29, 2026, 2:09 AM EDT
Completed No phase listed Observational

A Comparison of Two Ways to Manage Anti-HIV Treatment (The SMART Study)

NCT00027352
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
105
States / cities
Fremont, California • Los Angeles, California • San Francisco, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2009 · Synced Sep 29, 2026, 2:09 AM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination

NCT00006291
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC(2)120(B,MN)GNP (vCP1452), Aldesleukin
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 29, 2026, 2:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs

NCT00016718
View directory record Official record
Conditions
HIV Infections
Interventions
Didanosine (ddI), Efavirenz (EFV), Emtricitabine (FTC)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
90 Days to 21 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
16
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 29, 2026, 2:09 AM EDT
Completed Phase 1 Interventional

Safety of FMT Using Oral Encapsulated PRIM-DJ2727 in HIV

NCT03329560
View directory record Official record
Conditions
HIV-1-infection
Interventions
Oral fecal microbiota transplantation
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Sep 29, 2026, 2:09 AM EDT